Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.38 |
| ▸ | NPC1 | O15118 | 9/20 | 0.38 |
| ▸ | RAB9A | P51151 | 9/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.36 |
| ▸ | HPGD | P15428 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321553 | 0.74 | ALOX15 (0.48) | ALOX15ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL12728749 | 0.73 | ALOX15 (0.41) | ALOX15ALDH1A1NPC1RAB9AGAA | |
| SCHEMBL2008456 | 0.71 | ALOX15 (0.50) | ALOX15ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL276216 | 0.71 | ALOX15 (0.50) | ALOX15ALDH1A1NPC1RAB9ANFKB1 | |
| SCHEMBL20955977 | 0.71 | ALOX15 (0.50) | ALOX15ALDH1A1NPC1RAB9AGAA | |
| SCHEMBL24097278 | 0.71 | ALOX15 (0.50) | ALOX15ALDH1A1NPC1RAB9ANFKB1 | |
| SCHEMBL276215 | 0.71 | ALOX15 (0.50) | ALOX15ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL2008459 | 0.71 | ALOX15 (0.50) | ALOX15ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL12872524 | 0.71 | ALOX15 (0.44) | ALOX15ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL17083596 | 0.71 | ALOX15 (0.44) | ALOX15ALDH1A1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6572664-B2 | Oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2003-06-03 | — | — | US | claimed |
| US-20020170121-A9 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | L'OREAL S.A. (FR) | 2002-11-21 | — | — | US | claimed |
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | BRETON PHILIPPE (FR) | 2002-01-10 | — | — | US | claimed |
| EP-1129691-A2 | Compositions for dyeing keratinous fibers containing indolizine derivatives and dyeing method using same | L'OREAL (FR) | 2001-09-05 | — | — | EP | claimed |
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| EP-3557998-B1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023125841-A1 | HETEROCYCLIC COMPOUND AS POLθ INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20230167068-A1 | BENZOPYRAZOLE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-3733663-B1 | 1-[6-[[4-(PHENYLAMINO)-6-QUINAZOLINYL]OXY]-3-AZABICYCLO[3.1.1]HEPT-3-YL]-2-PROPEN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS IRREVERSIBLE INHIBITORS OF PAN-HER TYROSINE KINASE FOR THE TREATMENT OF CANCER | CHENGDU JINRUI FOUND BIOTECH CO LTD (CN) | 2023-05-17 | — | — | EP | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20070191445-A1 | heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2007-08-16 | — | — | US | disclosed |
| US-20070087998-A1 | Imidazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2007-04-19 | — | — | US | disclosed |
| US-6572664-B2 | Oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2003-06-03 | — | — | US | disclosed |
| US-20020170121-A9 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | L'OREAL S.A. (FR) | 2002-11-21 | — | — | US | disclosed |
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | BRETON PHILIPPE (FR) | 2002-01-10 | — | — | US | disclosed |
| EP-1129691-A2 | Compositions for dyeing keratinous fibers containing indolizine derivatives and dyeing method using same | L'OREAL (FR) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191445-A1 | heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors | HSP90AB1, HSP90AA1, HSP90AB2P | ALOX15 4030/4885ALDH1A1 1618/4885NPC1 1883/4885 |
| US-20230167068-A1 | BENZOPYRAZOLE COMPOUND | ABCB1, CYP3A43, CYP3A5 | ALOX15 2818/4885ALDH1A1 463/4885NPC1 237/4885 |
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | KRT18, INMT, IDO1 | ALOX15 1936/4885ALDH1A1 897/4885NPC1 4832/4885 |
| US-20020170121-A9 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | KRT18, INMT, IDO1 | ALOX15 1936/4885ALDH1A1 897/4885NPC1 4832/4885 |
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90B1, HSP90AA1 | ALOX15 3504/4885ALDH1A1 2165/4885NPC1 1235/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | ALOX15 2172/4885ALDH1A1 1036/4885NPC1 554/4885 |
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ERBB2, ERBB3, BRCA1 | ALOX15 4480/4885ALDH1A1 4139/4885NPC1 3640/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | ALOX15 4456/4885ALDH1A1 3447/4885NPC1 910/4885 |
| US-20070087998-A1 | Imidazole compounds that modulate HSP90 activity | HSP90AB1, HSP90AA1, HSP90B1 | ALOX15 4595/4885ALDH1A1 1480/4885NPC1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.